# A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

> **NCT00172107** · PHASE2 · COMPLETED · sponsor: **Shire** · enrollment: 217 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** ALX1-11 50 mcg
- **DRUG:** placebo
- **DRUG:** ALX1-11 75mcg
- **DRUG:** ALX1-11

## Key facts

- **NCT ID:** NCT00172107
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-05-18
- **Primary completion:** 1997-03-24
- **Final completion:** 1997-03-24
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2021-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00172107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00172107, "A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00172107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*